These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24777253)

  • 1. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.
    Cindolo L; Alvarez-Maestro M; Castellucci R; Schips L
    World J Urol; 2015 Mar; 33(3):441-2. PubMed ID: 24777253
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.
    Park T; Choi JY
    World J Urol; 2014 Aug; 32(4):1093-105. PubMed ID: 24500194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients.
    Wu XJ; Zhi Y; Zheng J; He P; Zhou XZ; Li WB; Zhou ZS
    Urology; 2014 Mar; 83(3):539-43. PubMed ID: 24246318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on "Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 2013;32:1123-7".
    Oelke M
    Neurourol Urodyn; 2013 Nov; 32(8):1128-9. PubMed ID: 23192914
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
    Na Y; Ye Z; Zhang S;
    Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 22017520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.
    Geitona M; Karabela P; Katsoulis IA; Kousoulakou H; Lyberopoulou E; Bitros E; Xaplanteris L; Papanicolaou S
    BMC Urol; 2014 Sep; 14():78. PubMed ID: 25255740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutasteride: a review of its use in the management of prostate disorders.
    Keam SJ; Scott LJ
    Drugs; 2008; 68(4):463-85. PubMed ID: 18318566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride for the treatment of benign prostatic hyperplasia.
    Wu C; Kapoor A
    Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutasteride (Avodart) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2002 Dec; 44(1146):109-10. PubMed ID: 12500154
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Nov; 174(5):1904-5. PubMed ID: 16217336
    [No Abstract]   [Full Text] [Related]  

  • 20. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.